Edap Tms S.A. (NASDAQ:EDAP) Sees Significant Growth in Short Interest

Edap Tms S.A. (NASDAQ:EDAP - Get Free Report) saw a large increase in short interest during the month of March. As of March 31st, there was short interest totalling 114,900 shares, an increase of 336.9% from the March 15th total of 26,300 shares. Based on an average daily volume of 107,800 shares, the short-interest ratio is presently 1.1 days. Currently, 0.3% of the company's stock are short sold.

Analyst Ratings Changes

Several equities analysts recently commented on EDAP shares. HC Wainwright reissued a "buy" rating and issued a $19.00 target price on shares of Edap Tms in a report on Friday, March 28th. Jefferies Financial Group restated a "hold" rating and set a $2.00 target price (down previously from $8.00) on shares of Edap Tms in a research note on Friday, April 4th. StockNews.com initiated coverage on shares of Edap Tms in a report on Sunday, April 13th. They set a "hold" rating on the stock. Finally, Piper Sandler lowered their target price on shares of Edap Tms from $5.00 to $4.50 and set an "overweight" rating for the company in a report on Friday, March 28th.

Edap Tms Stock Performance

Shares of EDAP stock traded up $0.07 during trading hours on Friday, hitting $1.38. The stock had a trading volume of 39,425 shares, compared to its average volume of 94,624. The stock's 50 day moving average is $2.15 and its 200 day moving average is $2.34. The firm has a market capitalization of $51.20 million, a PE ratio of -2.12 and a beta of 0.12. Edap Tms has a twelve month low of $1.26 and a twelve month high of $7.40. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.18 and a quick ratio of 1.46.

Edap Tms (NASDAQ:EDAP - Get Free Report) last issued its quarterly earnings data on Thursday, March 27th. The medical equipment provider reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.06. Edap Tms had a negative net margin of 34.92% and a negative return on equity of 44.21%. The company had revenue of $22.69 million for the quarter, compared to the consensus estimate of $20.83 million. As a group, research analysts forecast that Edap Tms will post -0.6 earnings per share for the current fiscal year.

Institutional Trading of Edap Tms

Several institutional investors and hedge funds have recently added to or reduced their stakes in EDAP. Millennium Management LLC raised its stake in shares of Edap Tms by 218.5% during the fourth quarter. Millennium Management LLC now owns 48,915 shares of the medical equipment provider's stock worth $108,000 after purchasing an additional 33,558 shares during the last quarter. BNP Paribas Financial Markets raised its position in Edap Tms by 111.5% during the 4th quarter. BNP Paribas Financial Markets now owns 48,650 shares of the medical equipment provider's stock worth $108,000 after buying an additional 25,650 shares during the last quarter. Jane Street Group LLC lifted its stake in shares of Edap Tms by 174.7% in the 4th quarter. Jane Street Group LLC now owns 31,361 shares of the medical equipment provider's stock worth $69,000 after acquiring an additional 73,361 shares during the period. Schonfeld Strategic Advisors LLC boosted its holdings in shares of Edap Tms by 48.5% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 160,800 shares of the medical equipment provider's stock valued at $355,000 after acquiring an additional 52,500 shares in the last quarter. Finally, Rock Springs Capital Management LP boosted its holdings in shares of Edap Tms by 1.5% in the fourth quarter. Rock Springs Capital Management LP now owns 1,591,800 shares of the medical equipment provider's stock valued at $3,518,000 after acquiring an additional 23,800 shares in the last quarter. 62.74% of the stock is owned by hedge funds and other institutional investors.

Edap Tms Company Profile

EDAP TMS SA is a holding company, which, through its subsidiary, engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. It operates through the High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) segments. The HIFU segment develops, manufactures, and markets devices for the minimally invasive ablation of certain types of localized tumors using HIFU technology.